BOXED O
WARNING O
: O
WARNING O
: O
ASTHMA-RELATED O
DEATH O
WARNING O
: O
ASTHMA-RELATED O
DEATH O
Long-acting O
beta2-adrenergic O
agonists O
( O
LABA O
) O
increase O
the O
risk O
of O
asthma B-NonOSE_AE
-related O
death B-NonOSE_AE
. O

Data O
from O
a O
large O
placebo-controlled O
US O
trial O
that O
compared O
the O
safety O
of O
another O
LABA O
( O
salmeterol O
) O
with O
placebo O
added O
to O
usual O
asthma B-Not_AE_Candidate
therapy O
showed O
an O
increase O
in O
asthma B-NonOSE_AE
-related O
deaths B-NonOSE_AE
in O
subjects O
receiving O
salmeterol O
. O

This O
finding O
with O
salmeterol O
is O
considered O
a O
class O
effect O
of O
all O
LABA O
, O
including O
vilanterol O
, O
one O
of O
the O
active O
ingredients O
in O
ANOROTM O
ELLIPTA O
( O
r O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

The O
safety O
and O
efficacy O
of O
ANORO O
ELLIPTA O
in O
patients O
with O
asthma B-Not_AE_Candidate
have O
not O
been O
established O
. O

ANORO O
ELLIPTA O
is O
not O
indicated O
for O
the O
treatment O
of O
asthma B-Not_AE_Candidate
. O

EXCERPT O
: O
WARNING O
: O
ASTHMA-RELATED O
DEATH O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Long-acting O
beta2-adrenergic O
agonists O
( O
LABA O
) O
, O
such O
as O
vilanterol O
, O
one O
of O
the O
active O
ingredients O
in O
ANORO O
ELLIPTA O
, O
increase O
the O
risk O
of O
asthma-related O
death O
. O

A O
placebo-controlled O
trial O
with O
another O
LABA O
( O
salmeterol O
) O
showed O
an O
increase O
in O
asthma-related O
deaths O
in O
subjects O
receiving O
salmeterol O
. O

This O
finding O
with O
salmeterol O
is O
considered O
a O
class O
effect O
of O
all O
LABA O
, O
including O
vilanterol O
. O

( O
5.1 O
) O
* O
The O
safety O
and O
efficacy O
of O
ANORO O
ELLIPTA O
in O
patients O
with O
asthma O
have O
not O
been O
established O
. O

ANORO O
ELLIPTA O
is O
not O
indicated O
for O
the O
treatment O
of O
asthma O
. O

( O
5.1 O
) O

